206 related articles for article (PubMed ID: 18235970)
1. Biological characteristics of dengue virus and potential targets for drug design.
Qi RF; Zhang L; Chi CW
Acta Biochim Biophys Sin (Shanghai); 2008 Feb; 40(2):91-101. PubMed ID: 18235970
[TBL] [Abstract][Full Text] [Related]
2. Peptides as Therapeutic Agents for Dengue Virus.
Chew MF; Poh KS; Poh CL
Int J Med Sci; 2017; 14(13):1342-1359. PubMed ID: 29200948
[TBL] [Abstract][Full Text] [Related]
3. Dengue Virus and Its Inhibitors: A Brief Review.
Tian YS; Zhou Y; Takagi T; Kameoka M; Kawashita N
Chem Pharm Bull (Tokyo); 2018; 66(3):191-206. PubMed ID: 29491253
[TBL] [Abstract][Full Text] [Related]
4. Novel concept on antiviral strategies to dengue.
Lo YC; Perng GC
Curr Opin Virol; 2016 Jun; 18():97-108. PubMed ID: 27284691
[TBL] [Abstract][Full Text] [Related]
5. Nordihydroguaiaretic acid (NDGA) inhibits replication and viral morphogenesis of dengue virus.
Soto-Acosta R; Bautista-Carbajal P; Syed GH; Siddiqui A; Del Angel RM
Antiviral Res; 2014 Sep; 109():132-40. PubMed ID: 25017471
[TBL] [Abstract][Full Text] [Related]
6. Dengue Virus Evolution under a Host-Targeted Antiviral.
Plummer E; Buck MD; Sanchez M; Greenbaum JA; Turner J; Grewal R; Klose B; Sampath A; Warfield KL; Peters B; Ramstedt U; Shresta S
J Virol; 2015 May; 89(10):5592-601. PubMed ID: 25762732
[TBL] [Abstract][Full Text] [Related]
7. The Antimalarial Compound Atovaquone Inhibits Zika and Dengue Virus Infection by Blocking E Protein-Mediated Membrane Fusion.
Yamamoto M; Ichinohe T; Watanabe A; Kobayashi A; Zhang R; Song J; Kawaguchi Y; Matsuda Z; Inoue JI
Viruses; 2020 Dec; 12(12):. PubMed ID: 33371476
[TBL] [Abstract][Full Text] [Related]
8. Dengue: recent advances in biology and current status of translational research.
Swaminathan S; Khanna N
Curr Mol Med; 2009 Mar; 9(2):152-73. PubMed ID: 19275624
[TBL] [Abstract][Full Text] [Related]
9. Drug repurposing approaches to fight Dengue virus infection and related diseases.
Botta L; Rivara M; Zuliani V; Radi M
Front Biosci (Landmark Ed); 2018 Jan; 23(6):997-1019. PubMed ID: 28930586
[TBL] [Abstract][Full Text] [Related]
10. The dengue virus non-structural 1 protein: risks and benefits.
Amorim JH; Alves RP; Boscardin SB; Ferreira LC
Virus Res; 2014 Mar; 181():53-60. PubMed ID: 24434336
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Role of Phenolic Compounds against Dengue Virus: A Review.
Loaiza-Cano V; Monsalve-Escudero LM; Filho CDSMB; Martinez-Gutierrez M; Sousa DP
Biomolecules; 2020 Dec; 11(1):. PubMed ID: 33374457
[TBL] [Abstract][Full Text] [Related]
12. The Development of Peptide-based Antimicrobial Agents against Dengue Virus.
Huang YW; Lee CT; Wang TC; Kao YC; Yang CH; Lin YM; Huang KS
Curr Protein Pept Sci; 2018; 19(10):998-1010. PubMed ID: 29852867
[TBL] [Abstract][Full Text] [Related]
13. Dengue Antiviral Development: A Continuing Journey.
Low JG; Gatsinga R; Vasudevan SG; Sampath A
Adv Exp Med Biol; 2018; 1062():319-332. PubMed ID: 29845542
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in antiviral drug development towards dengue virus.
Troost B; Smit JM
Curr Opin Virol; 2020 Aug; 43():9-21. PubMed ID: 32795907
[TBL] [Abstract][Full Text] [Related]
15. Experimental in vitro and in vivo systems for studying the innate immune response during dengue virus infections.
Kitab B; Kohara M; Tsukiyama-Kohara K
Arch Virol; 2018 Jul; 163(7):1717-1726. PubMed ID: 29520688
[TBL] [Abstract][Full Text] [Related]
16. Recent patents in dengue disease management.
K Shahid S
Pharm Pat Anal; 2020 Dec; 9(6):173-185. PubMed ID: 33350353
[TBL] [Abstract][Full Text] [Related]
17. Within-host viral dynamics of dengue serotype 1 infection.
Clapham HE; Tricou V; Van Vinh Chau N; Simmons CP; Ferguson NM
J R Soc Interface; 2014 Jul; 11(96):. PubMed ID: 24829280
[TBL] [Abstract][Full Text] [Related]
18. Oligonucleotide-Based Approaches to Inhibit Dengue Virus Replication.
Panda K; Alagarasu K; Parashar D
Molecules; 2021 Feb; 26(4):. PubMed ID: 33670247
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of lanatoside C against dengue virus infection.
Cheung YY; Chen KC; Chen H; Seng EK; Chu JJ
Antiviral Res; 2014 Nov; 111():93-9. PubMed ID: 25251726
[TBL] [Abstract][Full Text] [Related]
20. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.
Melino S; Paci M
FEBS J; 2007 Jun; 274(12):2986-3002. PubMed ID: 17509079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
